{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007060","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.137660+00:00","generated_at":"2026-05-22T01:08:58.336485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protalix BioTherapeutics Q1 revenue up 170% to $10.0M, net loss narrows to $3.6M","bullets":["Revenues from selling goods $10.0M, up 170% YoY, driven by $5.9M increase in sales to Pfizer.","Net loss $3.6M ($0.05/sh) vs $4.6M ($0.06/sh) in Q1 2024; cash $34.7M.","Phase II trial of gout candidate PRX-115 expected to start H2 2025 after positive FIH results.","R&D expenses $3.5M (+21% YoY) due to clinical pipeline advancement; SG&A down 16% to $2.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007060","json":"https://secwatch.observer/filing/0001558370-25-007060.json","markdown":"https://secwatch.observer/filing/0001558370-25-007060.md","text":"https://secwatch.observer/filing/0001558370-25-007060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/0001558370-25-007060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/plx-20250509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:08:58.336485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}